IDH2 and acute myeloid leukemia: Enasidenib is a first‐in‐class, selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) proteins that is indicated for the treatment of adult patients with R/R AML with an IDH2 mutation (mIDH2+) in the United States.9, 10, 11, 12, 13